Myriad Genetics' study shows online tools increase hereditary cancer testing completion among patients, enhancing education and provider confidence.
Quiver AI Summary
Myriad Genetics, Inc. announced a study indicating that the use of its online screening tool, MyGeneHistory®, alongside a virtual education program, significantly increased the completion rates for hereditary cancer testing among patients. The research, published in Obstetrics & Gynecology and featured by the American College of Obstetricians and Gynecologists, found that these tools helped identify more patients eligible for testing and improved their understanding of genetic testing. Following the implementation of these resources, 30% more patients were identified as meeting guidelines for testing, 50% more were offered testing, and the completion rate more than doubled. Clinicians reported enhanced confidence in hereditary cancer risk assessment practices, with many expressing intentions to continue using the program. Myriad Genetics emphasizes its commitment to improving patient access to genetic testing through these innovative tools.
Potential Positives
- The study demonstrated a significant increase of 30% in the number of patients identified as meeting the guidelines for hereditary cancer testing after using the MyGeneHistory tool.
- The implementation of the online screening and education program resulted in a 50% increase in patients who were offered hereditary cancer testing, indicating enhanced clinician engagement.
- The completion rate of hereditary cancer testing more than doubled, showcasing improved patient participation and access to essential health services.
- Clinicians reported increased confidence in administering hereditary cancer risk assessments, with over 80% expressing their intention to continue using the program, suggesting strong provider satisfaction and potential for ongoing partnerships.
Potential Negatives
- The press release heavily relies on positive results from a single study, which may not fully represent broader outcomes or sustained effectiveness across diverse patient populations.
- The company's emphasis on the innovative tools and resources could suggest that their previous methods of patient screening and education were inadequate, potentially impacting their credibility.
- The mention of "forward-looking statements" implies uncertainty and risk associated with future outcomes, which may raise concerns for investors regarding the sustainability of the reported success.
FAQ
What is the purpose of MyGeneHistory®?
MyGeneHistory® is an online patient screening tool designed to help identify individuals who meet guidelines for hereditary cancer testing.
How did the study affect cancer testing rates?
The study found a 30% increase in patients identified for hereditary cancer testing after using the online tool and education program.
Why is patient education important in genetic testing?
Patient education improved understanding of genetic testing, leading to 50% more patients being offered hereditary cancer testing.
What support did clinicians report from the study?
Clinicians reported increased confidence in hereditary cancer risk assessment, with 87% noting the tools helped adhere to recommended care standards.
How many patients participated in the study?
The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYGN Insider Trading Activity
$MYGN insiders have traded $MYGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:
- COLLEEN F REITAN sold 46,012 shares for an estimated $1,285,851
- PAUL J DIAZ (President and CEO) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $744,750.
- MARGARET ANCONA (SVP, Chief of Staff) sold 11,538 shares for an estimated $320,987
- HEINRICH DREISMANN sold 10,000 shares for an estimated $270,520
- RASHMI KUMAR sold 7,500 shares for an estimated $210,075
- DALE MUZZEY (Chief Scientific Officer) sold 2,100 shares for an estimated $54,961
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MYGN Hedge Fund Activity
We have seen 125 institutional investors add shares of $MYGN stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 2,486,902 shares (-66.3%) from their portfolio in Q3 2024, for an estimated $68,116,245
- CITADEL ADVISORS LLC removed 1,695,989 shares (-96.1%) from their portfolio in Q3 2024, for an estimated $46,453,138
- CAMBER CAPITAL MANAGEMENT LP removed 1,550,000 shares (-28.2%) from their portfolio in Q3 2024, for an estimated $42,454,500
- WELLINGTON MANAGEMENT GROUP LLP removed 1,545,842 shares (-18.7%) from their portfolio in Q3 2024, for an estimated $42,340,612
- LOOMIS SAYLES & CO L P added 1,326,497 shares (+153.7%) to their portfolio in Q3 2024, for an estimated $36,332,752
- MILLENNIUM MANAGEMENT LLC added 777,499 shares (+17.7%) to their portfolio in Q3 2024, for an estimated $21,295,697
- MORGAN STANLEY removed 491,650 shares (-35.8%) from their portfolio in Q3 2024, for an estimated $13,466,293
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) --
Myriad Genetics, Inc
. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The
study
was published in
Obstetrics & Gynecology
(also known as
The Green Journal)
and was highlighted in the
American College of Obstetricians and Gynecologists (ACOG) Daily Bulletin
.
The study evaluated the change in genetic testing completion rate following the implementation of
MyGeneHistory
®
, a guideline-based online patient screening tool, and a virtual patient education program. It found that the online tool enabled identification of significantly more patients meeting guideline-based criteria for hereditary cancer testing (HCT), while the education program improved the patients’ understanding of genetic testing.
“Approximately one in four women meet the guidelines for hereditary cancer testing
1
,” said Richard N. Waldman, MD, lead author of the study, past president of ACOG, and a Diplomate of the American Board of Obstetrics and Gynecology. “By implementing easy-to-use online patient screening and education tools, clinicians were better able to identify patients who would benefit from genetic testing, which could lead to more personalized screening and preventive measures.”
Following the practices’ implementation of MyGeneHistory and the patient education program:
30% more patients were identified as meeting the guidelines for HCT;
50% more patients who met guidelines were offered HCT; and
More than twice the number of patients completed HCT.
Clinicians participating in the study reported increased confidence in administering hereditary cancer risk assessment (HCRA), with 87% stating the online screening and education tools helped them practice according to the recommended standard of care. More than 80% of providers believed the program helped them follow the ACOG guidelines for HCRA and expressed their intention to continue using the program.
“These findings further support Myriad’s commitment to provider ease of use and patient access by enabling an always-on tool to drive appropriate patient identification and education, via our Breast Cancer Risk Assessment Program,” said Melissa Gonzales, President of Women’s Health, Myriad Genetics.
Myriad’s Breast Cancer Risk Assessment Program features the
MyRisk
®
with RiskScore
®
Hereditary Cancer Test
, the first and industry-leading hereditary cancer test and polygenic breast cancer risk assessment for all ancestries. It includes MyGeneHistory, an online screening tool that helps assess if a patient meets medical guidelines for hereditary cancer testing. The program also includes patient education about genetic testing and a guide on how to collect family history of certain cancers. For more information, please visit
Myriad.com/seemore
.
About the Study
The large-scale prospective study involved more than 10,000 patients across five U.S. community obstetrics/gynecology practices. The study included an eight-week observation period, followed by three to four weeks of training on the online patient screening and virtual patient education program, which include a pre-recorded video with/without a genetic counselor phone call. Following a four-week practice period, the study authors evaluated hereditary cancer risk assessment and patient education metrics at eight weeks. This data was then compared with pre-intervention metrics using univariate conditional logistic regression models stratified by site.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit
www.myriad.com
.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the study's findings further support the company’s commitment to provider ease of use and patient access and statements related to how implementing an easy-to-use online patient screening and education tool may lead to clinicians being better able to identify patients who would benefit from genetic testing, which could lead to more personalized screening and preventive measures. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
____________________________
1
DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting.
Obstetrics & Gynecology
2018
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
